GT 01123
Alternative Names: Glycosylated GLP-1 analogue; GT-01123Latest Information Update: 28 Aug 2023
At a glance
- Originator Glytech
- Class Antihyperglycaemics; Glucagon-like peptides
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Type 2 diabetes mellitus
Most Recent Events
- 28 Aug 2023 GT 01123 is available for licensing as of 28 Aug 2023. https://www.glytech-inc.com/pipeline/
- 27 Jul 2023 Preclinical trials in Type 2 diabetes mellitus in Japan (unspecified route), prior to July 2023 (Glytech pipeline, July 2023)